Update: NHSN Point of Care Test Result Reporting

On October 19, 2020, HHS updated its reporting guidance to indicate that CMS-certified long-term care facilities are required to use NHSN to meet this reporting requirement. Specifically, the HHS guidance states that:

“CMS-certified long-term care facilities shall submit point-of-care SARS-CoV-2 testing data, including antigen testing data, to CDC’s National Healthcare Safety Network (NHSN). This requirement to submit data to CDC’s NHSN applies only to CMS-certified long-term care facilities. Test data submitted to NHSN will be reported to appropriate state and local health departments using standard electronic laboratory messages. Other types of long-term care facilities may voluntarily report testing data in NHSN for self-tracking or to fulfill state or local reporting requirements, if any.”
In order to utilize the new pathway to fulfill reporting requirements, nursing homes and other long-term care facilities that are NHSN users will need to upgrade their NHSN Secure Access Management Service (SAMS) from Level 1 to Level 3. CDC is working closely with facilities to assist them in this process. An email invitation from CDC to perform this upgrade will be sent to users.

Alternatively, facilities can email nhsn@cdc.gov with the subject line “Enhancing Data Security” to begin upgrading their SAMS access to use this Pathway. LTCF’s can also refer to the following link: Increasing LTCF SAMS Level Access to NHSN.

If there are additional questions regarding the NHSN process, please E-mail DOHInfectionControl@state.sd.us.
The NHSN Team is happy to announce that the training for the new NHSN Long-term Care Facility COVID-19 Point of Care (POC) Test Reporting Tool has been rescheduled. The October 30th training will be live and allow for submission of audience questions.

The November 2nd training will be a rebroadcast of the recorded training followed by a live Q & A session. A recording of the original webinar will be posted for on-line viewing.

Please join us for one of the following trainings. Both webinars are identical in content, so please plan to attend once.

**Title:** Reporting Results of Point of Care Testing for COVID-19: A New NHSN Tool  
**Date:** Friday, Oct 30, 2020  
**Time:** 2:00 – 3:00 PM ET

Space is limited, register in advance for this meeting: https://cdc.zoomgov.com/meeting/register/vJIsduGgqzksGXKmF_rzfbM_gwu1NaLWuB8

After registering, you will receive a confirmation email containing information about joining the meeting.

**Title:** Reporting Results of Point of Care Testing for COVID-19: A New NHSN Pathway  
**Date:** Monday, Nov 2, 2020  
**Time:** 12:30 – 1:30 PM ET

Space is limited, register in advance for this meeting: https://cdc.zoomgov.com/meeting/register/vJIsqemvrgoH2HEz6621xB-xPjz8Q8jMKE

After registering, you will receive a confirmation email containing information about joining the meeting.
This week's IP Webinars offered by NETEC

- **Community Health Considerations: Infection Prevention**
  - **Wednesday, October 28, 2020 | 1:00 PM EST**
  - See Website for recording

- **Influenza in the Age of COVID**
  - **Friday, October 30, 2020 | 1:00 PM EST**

Sign up at: https://netec.org/
Laboratory Guidance
Statewide Priority Populations for SARS-CoV-2 Testing

It is a statewide priority that ALL individuals with symptoms of COVID-19 be tested for SARS-CoV-2 with the recommendation from a health care provider

- Hospitalized individuals
- Healthcare workers, first responders, and active military
- Critical infrastructure workers in food manufacturing and agriculture
- Individuals in communal living settings like long-term care facilities
- Underinsured or uninsured individuals
- Low-income individuals or individuals unable to pay for testing
- Homeless individuals
**SDPHL COVID-19 Testing Priorities**

- **Symptomatic** hospitalized patients
- **Symptomatic** healthcare workers, first responders, and active military
- **Symptomatic** individuals in congregate living settings like LTC facilities
- **Symptomatic** individuals with no way to pay for testing

- **Asymptomatic** participants in state-sponsored sentinel surveillance:
  - Long-term care (staff and residents)
  - K-12 schools (adults)
  - Corrections (inmates and staff)
  - Tribes (tribal members)
Reminders from the SDPHL Team

✓ Every specimen must have two patient identifiers on the specimen tube.
✓ Use packaging and shipping provided by the SDPHL when shipping specimens to the state public health laboratory.
✓ Swab specimens submitted in traditional viral transport media are tested everyday.
✓ Specimens submitted in Hologic Aptima collection kits are not tested every day; specimen submitted in Aptima kits may be subject to testing delays if they are not submitted on the appropriate days each week.

**Please reach out to the SDPHL with questions about packaging and shipping materials and collection kit use (605-773-3368).
Abbott ID Now Allocation: 10/29-11/4

- Manufacture of ID Now test kits was disrupted during the week of 10/19
- ID Now allocation from SDPHL to hospitals and clinics resumed the week of 10/26
- ID Now allocation is still significantly lower than demand
Abbott ID Now: Recommendations for Use

1. Does the patient have symptoms consistent with COVID-19?
   - Yes
   - No

2. Does the patient require rapid* COVID-19 testing?
   - Yes
   - No

3. Perform ID Now COVID-19 testing using SDDOH-provided resources and report all results, positive or negative, to SDDOH within 24 hours.

*Health care providers should determine which patients require rapid testing rather than traditional send-out testing which can take several days. Examples of patients that might require rapid testing include healthcare workers, critical infrastructure workers, severely ill individuals, or other individuals that meet SDDOH high-priority definition.
SDPHL and other laboratories are receiving daily requests to confirm antigen test results.

Given the high prevalence of COVID-19 in our communities, confirmation of antigen test results is most relevant for the following:

- Symptomatic individuals who test negative for SARS-CoV-2 using an antigen test.
FDA EUA Updates

• FDA has issued Emergency Use Authorization for the following:
  – 187 (2): Molecular Diagnostic Tests for SARS-CoV-2
  – 56: Serological Tests
  – 34: Molecular-Based Laboratory Developed Tests for SARS-CoV-2
  – 7 (1): Antigen Diagnostic Tests for SARS-CoV-2

• Notable Updates:
  – Antigen Test: Celltrion COVID-19 MIA (magnetic immunoassay)
  – Diagnostic Test: T2 Biosystems T2SARS-CoV-2 Panel (T2 magnetic resonance)